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Abstract The methylation of O6-methylguanine DNA
methyltransferase (MGMT) gene promoter is a key bio-
logical marker in clinical neuro-oncology. Nevertheless,
there is no consensus concerning the best technique for its
assessment. In a recent study comparing five methods to
analyze MGMT status, we found that the best prediction of
survival was obtained with a pyrosequencing (PSQ) test
assessing methylation of 5 CpGs (CpGs 74–78). In the
present study we extended our PSQ analysis to 16 CpGs
(CpGs 74–89) identified as critical for transcriptional
control of the gene. The predictive value of the methylation
levels at each CpG, as well as the mean methylation levels
of selected sets of consecutive CpGs was tested in a cohort
of 89 de novo glioblastoma patients who had received
standard of care treatment (Stupp protocol). Using an
optimal risk cut-off, each CpG or combination of CpGs,
was associated with overall survival (OS) and progression
free survival. The best predictive models for OS after
stratification on performance score and age were obtained
with CpG 89, CpG 84 and mean methylation of CpG 84–88
(Hazard ratio (HR), 0.31; p \ 0.0001). The improvement
compared to the predictive value of the test analyzing
average methylation of CpG 74–78 (HR, 0.32; p \ 0.0001)
was however marginal. We recommend to test CpGs 74–78
when analyzing MGMT methylation status by PSQ
because a commercial kit that has successfully been used in
several studies is available, allowing reproducible and
comparable results from one laboratory to another.
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Introduction
Since the introduction of temozolomide (TMZ) chemo-
therapy in the standard care protocol for glioblastoma
(GBM) patients, the analysis of O6-methylguanine DNA
methyltransferase (MGMT) status has become a key bio-
logical marker. MGMT is a DNA repair protein which
removes alkyl adducts on the O6 position of guanine,
inducing resistance against alkylating agents such as TMZ.
MGMT status is currently used to stratify patients in
clinical trials, such as in the RTOG 0525 randomized phase
III trial that compared standard adjuvant TMZ with a dose-
dense schedule in newly diagnosed GBM patients [1]. It
was also used to select patients in the CENTRIC phase III
trial that assesses the usefulness of adding cilengitide to the
standard treatment in newly diagnosed GBM patients [2].
As MGMT status is a strong predictive factor of response
to treatment with TMZ [3], it is determined in most on-
going clinical trials using this drug. The recently published
results of the NOA-08 trial on elderly malignant astrocy-
toma patients and the Nordic trial on elderly GBM patients
showed that elderly malignant astrocytoma patients with
methylated MGMT promoter may receive as much benefit
from TMZ as from radiotherapy alone. This suggests that
testing MGMT methylation status may help treatment
decision making in these patients, which might increase the
demand for MGMT methylation test in clinical practice
[4].
Despite the increasing needs for MGMT methylation
testing, there is no consensus concerning the best technique
for its assessment. MGMT is mainly regulated at the epi-
genetic level: the methylation of the MGMT CpG island
silences the gene and therefore is associated with a lack of
MGMT protein expression. Most studies reporting a link
between MGMT status and survival in GBM patients have
used techniques based on DNA methylation [5]. These
techniques are designed to detect methylated (or unme-
thylated) CpGs located in exon 1 and immediately down-
stream, under the assumption that methylation of these
CpGs reflects protein expression and therefore can predict
response to TMZ. The CpG island of MGMT includes 98
CpG sites [6] and it has been shown that the patterns of
methylation are rather heterogeneous. Some studies
investigated to determine which CpG sites are critical for
MGMT expression. Everhard et al. studied methylation at
52 CpG sites by pyrosequencing (PSQ) in GBM and
compared the results with mRNA expression. These
authors found that methylations of the whole 52 CpGs
(CpGs 12–46 and CpGs 71–97), as well as CpG 27, 32,
32–33, 72–83, 73, 75, 79 and 80 were significantly corre-
lated with expression. Shah et al. analyzed the methylation
profile of 97 CpGs by bisulfite sequencing of GBM tissues
and correlated the results with mRNA and protein
expressions. 39 CpGs and 25 CpGs were significantly
correlated with mRNA and protein expression, respectively
[7]. Malley et al. studied the methylation status of the
entire CpG island of MGMT using PSQ and compared it
with MGMT mRNA expression in GBM cell lines and
xenografts. They identified two separate regions (spanning
CpG 25–50 and CpG 73–90) where methylation was sig-
nificantly correlated with expression. Furthermore, using a
luciferase reporter assay they showed that individual CpGs
(in particular CpG 89) can play a significant role in MGMT
promoter activity [6]. The primers commonly used for the
methylation-specific PCR technique (MSP) bind to
sequences encompassing CpGs 76–80 (forward) and CpGs
84–87 (reverse) [8]. As a derived method, a real-time-
quantitative PCR-based MSP, developed by MDxHealth
(Lie`ge, Belgium), which has been applied in several
international clinical trials and is used for MGMT testing
by some clinical laboratories, such as LabCorp in north
America, utilizes primers that include CpGs 76–80 and
CpGs 88–90. This technique generally detects MGMT
methylation in about 30 % of GBM [1, 9]. These MSP-
based techniques have the potential drawback of failing to
detect heterogeneous methylation because primers are
designed to amplify sequences where all CpGs are fully
methylated. Another drawback of using a commercial
service is a high cost and the long turnover time, which is
not always suitable in a day-to-day practice.
In our recent study in which we compared five methods
(MS-PCR, MethyLight, PSQ, MS-HRM and IHC) to ana-
lyze MGMT status in a series of 100 GBM patients who
had received standard care treatment (Radiotherapy plus
concomitant adjuvant TMZ chemotherapy), we found that
the best prediction of survival was obtained with PSQ [10].
PSQ allows quantification of methylation at each individ-
ual CpG and therefore can detect heterogeneous methyla-
tion. The PSQ assay used in this previous study examined 5
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CpG sites (CpGs 74–78, PyroMark Q96 CpG MGMT kit,
Qiagen). However, some of the critical CpGs for MGMT
promoter were not included. In an attempt to determine the
clinically most relevant CpGs for MGMT methylation
assessment, we extended our PSQ analysis to cover CpG
74 through CpG 89 in one subset of patients and tested the
impact of methylation at each CpG site as well as the
average methylation values of selected consecutive CpGs
on predicting patient survival.
Materials and methods
Patients and tumor samples
The patients with newly diagnosed primary GBM selected
in this study were given standard care treatment (the so-
called Stupp protocol) and followed up for at least
18 months. These patients form a cohort included in a
French multicentre study that compared five techniques
(MS-PCR, MS-HRM, PSQ, MethyLight and immunohis-
tochemistry) for assessing MGMT status [10]. The protocol
was approved by the Rennes medical ethics committee and
informed consents were obtained from the patients. Tumor
samples obtained during surgery were stored at -80 C,
and only samples containing at least 60 % of tumor cells
were processed for DNA extraction. Bisulfite modification
of DNA was performed using the EZ DNA methylation
Gold kit according to the specified protocol (Zymo
Research, Orange, CA). DNA extracted from peripheral
blood mononuclear cells and from primary cell lines were
used as non-methylated and methylated controls, respec-
tively. For the independent cohort of validation, DNA was
extracted from FFPE tissues with the QIAmp DNA FFPE
tissue kit (Qiagen, Courtaboeuf, France).
Pyrosequencing analysis
Templates for PSQ were prepared by amplifying bisulfite
modified DNA with a forward primer (GTTTYGGATATG
TTGGGATAG) and a biotinylated reverse primer (AAAA
CCACTCRAAACTACCAC). Two assays were designed
and run on this template using two PSQ primers: GAT-
AGTTYGYGTTTTTAGAA (assay for CpGs 74–83) and
GYGATTTGGTGAGTGTTTG (assay for CpGs 84–89).
PSQ was performed using PyroGold Q96 SQA Reagents
and the Pyro Q-CpG software on a PyroMark ID pyro-
sequencer (Qiagen, Crawley, UK) as per manufacturer’s
recommendation. Full details for CpG location and PSQ
can be found in Malley et al. [6] and Mullolland et al. [11].
Statistical analysis
The statistical analysis was performed using the R statis-
tical software (version 2.13.0, http://www.Rproject.org).
For each of the 16 tested CpG, as well as for the mean of
consecutive selected CpGs, an optimal risk cut-off was
determined as the threshold value of the continuous dis-
tribution which best discriminates low- and high-risk
patients according to their outcomes (outcome-based
method). More precisely, these values were defined as the
thresholds that optimized the area under the ROC curve
obtained with a Cox model [12] using overall survival (OS)
and progression-free survival (PFS) adjusted for age and
Karnofsky score (the proportional hazard assumption was
checked). Age, sex, performance status and extent of sur-
gery were analyzed as potential prognostic factors and
variables with p \ 0.2 for log-rank test were introduced as
adjustment factors. The function risksetAUC (package
risksetROC) in the R statistical software was used to obtain
the Area Under the ROC Curve. For each variable, the
Harrell’s C index [13] was also calculated with the validate
function (in Design package). Harrell’s C index after
bootstrap is a measure of predictive discrimination defined
as the proportion of all randomly selected pairs of patients
in which the predictions and outcomes are concordant. For
example, if the predicted survival time is higher for the
patient living longer, the predictions for that pair are said to
be concordant with the outcomes. A value of 0.5 indicates
agreement by chance and a value of 1.0 indicates perfect
discrimination.
To study OS and PFS, cumulative event curves (cen-
sored endpoints) were established using the Kaplan–Meier
method.
Results
Study population
The study population included 89 adult patients with newly
diagnosed primary GBM, excluding giant-cell GBM.
Patients were treated between November 2003 and Sep-
tember 2007. Clinical patient characteristics are summa-
rized in Table 1. The median PFS was 9.0 months
(10.5–12.7; 95 % CI) and median OS was 16.5 months
(18.5–20.8; 95 % CI). The independent validation cohort
comprised 50 newly diagnosed GBM patients treated with
radiotherapy and concurrent/adjuvant TMZ. Their median
age at surgery was 59 years (range, 41–78 years) and
median OS was 17.2 months (14.7–21.1; 95 % CI). The
KPS was \70 for 5 patients, between 70 and 80 for 23
patients and between 90 and 100 for 22 patients.
J Neurooncol
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Methylation levels of the 16 CpGs in the patient cohort
As previously described, we observed a heterogeneous
pattern of methylation for some tumors (Fig. 1a). Inter-
estingly, some of these samples with heterogeneous
methylation were found to be unmethyalted when tested
with MS-PCR (data not shown). The levels of methylation
were highly variable from one tumor to another (mean
methylation levels of all CpGs ranged from 0 to 67 %).
Values from 0 to 89 % were observed for a single CpG.
When considering the mean and median methylations
levels at each site, values tended to be slightly higher for
CpG 82 through CpG 89 (Fig. 1b). The highest values were
observed for GpGs 82, 87 and 89. Interestingly, this pattern
of methylation was also observed for non-tumoral samples,
with higher values for CpGs 87 and 89 (data not shown).
Prognostic impact of CpG methylation
We first considered the prognostic impact of each CpG
separately (Table 2). The variables were dichotomized
according to their optimized cut-offs. For OS, the best
AUCROC values at an individual CpG site were obtained
for CpGs 89, 84, 75 and 87 using cut-offs of 12, 9, 11 and
25 % respectively. Interestingly, variations observed for
the optimized cut-offs followed the same patterns observed
for the median values at a given CpG; in particular, the
median values, as well as the optimized cut-offs were
higher for CpGs 82, 87 and 89. For PFS, the best AUCROC
values were obtained for CpGs 76 and 84 using cut-offs of
8 and 9 % respectively. We also tested the mean of the
following sets of CpGs as variables: all of the 16 CpGs
(74–89), the 6 CpGs included in the second PSQ assay
(CpGs 84–89), every combination of the five consecutive
CpGs included in the first or second PSQ assay (from
74–78 to 79–83 for the first assay; 84–88 and 85–89 for the
second assay), and the CpGs 76–79. CpGs 74–78 are tested
with the PyroMark Q96 CpG MGMT kit (ref. 972032) and
the PyroMark Q24 CpG MGMT kit (ref. 970032) provided
by Qiagen. These kits are adapted for the PyroMark Q96
ID System and PyroMark Q24 MDx System, respectively
and have already been used in several studies [10, 14–17].
CpGs 76–79 are tested in another MGMT PSQ kit (Pyro-
Mark Q24 CpG MGMT) developed by Qiagen for the
PyroMark Q24 MDx System (ref. 970061). Among the best
variables associated with both OS and PFS, we found CpG
84, CpG 89 and the means of CpGs 84–88, 74–78 and
76–80.
The percentage of patients considered as methylated
when using a cut-off optimized for OS ranged from 39 %
(cut-off 8 % for CpG 74) to 57 % (cut-off 5 % for CpG
85). The percentage of patients considered as methylated
when using a cut-off optimized for PFS ranged from 34 %
(cut-off 32 % for mean CpG 85–89) to 55 % (cut-off 4 %
for CpG 81). Figure 2 presents the plots of Kaplan–Meier
survival curves showing the OS and PFS of patients
dichotomized according to the optimized cut-off values
obtained for CpG 89, CpG 84 and the means of CpG
84–88, 74–78, 76–79.
All the tested variables (single CpGs as well as means of
selected consecutive CpGs) allowed us to discriminate
groups of patients with statistically different OS and PFS.
However, some variables such as CpG 84, CpG 89 and the
means of CpGs 84–88, 74–78 were among the most pow-
erful predictors of survival in our series of GBM patients
treated with TMZ.
We also calculated cut-off values in our series of
patients by a bootstrap procedure based on 1,000 resam-
plings (see online resource, Supp Table 1). For OS, means
of the 1,000 cut-offs obtained with optimization of AUC of
the Cox model and their confidence intervals were 11 %
(4–21 %), 18 % (4–35 %), 10 % (4–28 %) and 16 %
(4–28 %) for CpG 84, CpG 89, CpGs 74–78, and CpGs
84–88, respectively. For PFS, means of the cut-offs and
their confidence intervals were 12 % (4–25 %), 23 %
(4–54 %), 9 % (4–20 %) and 18 % (6–30 %) for CpG 84,
CpG 89, CpGs 74–78, and CpGs 84–88, respectively. The
different cut-offs for CpG 74–78 were tested in an inde-
pendent cohort of 50 newly diagnosed GBM patients. As
frozen tumor tissue is not always available in daily prac-
tice, for this cohort, DNA was extracted from FFPE tissues.
The best prognostic effect for OS was observed at the 9 %
Table 1 Patients characteristics
Median age at surgery in years (range) 58 (21.0–73.0)
Gender (n)
Females 35
Males 54
Type of surgery (n)
Total resection 63
Partial resection 20
Biopsy 6
KPS (n)
90–100 25
70–80 50
\70 14
Cycles of TMZ in adjuvant (n)
Median (range) 6 (0–21)
Treatment at recurrence (n)
Chemotherapy with nitrosourea 30
Surgery with chemotherapy 13
Bevacizumab with irinotecan 7
Other treatment 11
No treatment 28
KPS Karnofsky Performance Status, TMZ Temozolomide
J Neurooncol
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Fig. 1 Percentages of methylation levels at the different tested CpGs. a Examples of heterogeneous pattern of methylation for 6 tumor samples.
b Mean (square) and median (circle) percentages of methylation levels at the different tested CpGs for the series of patients analyzed
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CpG 89
45 (51%)
44 (49%)
P = 1,30E-05
CpG 84
40 (45%)
49 (55%)
P = 3,00E-05
CpG 84-88
P = 2,80E-05
38 (43%)
51 (57%)
CpG 74-78
P = 4,00E-05
39 (44%)
50 (56%)
CpG 76-79
P = 1,53E-04
38 (43%)
51 (57%)
Median time to death
in months (95% CI)
M :    24.1 (20.2–NR)
UM : 14.9 (12.9-17.9)
A/OS rate
CpG 84
P = 3,00E-06
40 (45%)
49 (55%)
CpG 89
P = 8,00E-06
43 (48%)
46 (52%)
CpG 74-78
P = 6,00E-06
41 (46%)
48 (54%)
CpG 84-88
P = 7,00E-06
38 (43%)
51 (57%)
CpG 76-79
P = 2,30E-05
36 (40%)
53 (60%)
B/PFS rate
M    : 24.1 (20.2–NR)
UM : 15.8 (13.7-18.6)
M    : 26.2 (20.4–NR)
UM : 15.8 (13.9-18.6)
M    : 26.2 (20.2–NR)
UM : 15.9 (13.7-18.6)
M    : 26.0 (19.3–NR)
UM : 16.0 (13.9-18.6)
Median time to progression
in months (95% CI)
M :    14.0 (11.8–19.9)
UM :  9,0 (8.2-10.3)
M    : 14.6 (12.2–24.1)
UM : 9.0 (8.3-10.6)
M    : 14.0 (12.2–22.6)
UM : 9.0 (8.3-10.3)
M    : 14.6 (11.8–24.1)
UM : 9.0 (8.5-10.7)
M :    13.9 (12.2–22.6)
UM :  9.0 (8.2-10.6)
A B
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cut-off: patients with a PSQ-assessed mean percentage of
methylation above nine (34 %) had a median OS of
26.2 months whereas patients with a mean percentage of
methylation of nine or below had a median OS of
14.8 months (p = 8.8E-04) (Fig. 3).
Discussion
Methylation status of MGMT is currently recognized as a
strong prognostic and predictive factor for newly diagnosed
GBM patients treated by TMZ in an adjuvant setting [3, 10,
14–16, 18–21]. However, there is a wide choice of tech-
niques to assess methylation and depending on the method,
the percentage of patients classified as potential responders
to alkylating agents can vary greatly, as we have recently
pointed out [10]. PSQ has been shown to be a robust
technique, with good clinical performances in predicting
TMZ response, according to the results of different studies.
With a cut-off between 8 and 10 % (average of all CpGs
tested), from 42 to 53 % of patients are considered as
methylated [10, 14–16, 18]. However, other CpGs, apart
from the 5 CpGs (74–78) analyzed in most of these studies
can play a critical role in the transcriptional control of
MGMT, and could therefore be useful biomarkers to predict
the outcome of GBM patients treated with TMZ. In our
study, we analyzed 16 CpGs by PSQ with a custom-
designed test and sought to determine which individual
CpG, or combination of CpGs is best at predicting thera-
peutic response in a cohort of newly diagnosed GBM
patients that were treated with the Stupp regimen.
Among the topmost ten ranking GpGs or means of CpGs
associated with outcome, we found CpGs 89, means of
CpGs 84–88, 85–89 and 74–89. Substitution of CpGs 89,
CpGs 84–87 and CpGs 76–87 has been shown to signifi-
cantly attenuate promoter activity of MGMT in a luciferase
reporter assay [6]. This firmly supports the hypothesis that
MGMT methylation impacts the survival of patients
through a decreased expression of MGMT that would
reduce resistance against alkylating agents. A similar
conclusion was drawn from the study of Bady et al. These
authors compared the MGMT CpG methylation levels
obtained by the HumanMethylation 450 BeadChips (Illu-
mina) to MGMT expression and the patients’ outcome.
Among the 18 probes of interest located in or near the
promoter region, the two CpGs showing the strongest
correlation with expression (CpG 31 and CpG 84 in our
study) were also those best correlated with outcome [22]. It
is of note that the methylation levels of CpG 84, which is
the only CpG interrogated by their BeadChip among the 16
CpGs we tested, is also well correlated with the patients’
outcome in our study.
A major issue for quantitative techniques such as PSQ
is the determination of a cut-off to dichotomize patients
into methylated and unmethylated status. To allow com-
parisons among the tested CpGs, we calculated an optimal
bFig. 2 Kaplan–Meier analysis of overall survival (OS) (a) and
progression free survival (PFS) (b) according to MGMT promoter
methylation status obtained with different CpGs or means of selected
CpGs. M patients with a value above the calculated cut-off and
therefore considered as methylated, UM patients with a value below
or equal to the calculated cut-off and therefore considered as
unmethylated. NR not reached
Median time to death
in months (95% CI)
M :    26.2 (17.6–NR)
UM : 14.8 (14.2-19.2)
M :    26.2 (13.5–NR)
UM : 16.5 (14.6-19.3)
M :    23.7 (17.2–NR)
UM : 14.9 (14.2-19.2)
CpG 74-78
P = 8,8E-04
HR = 0,27
17/50 (34%)
33/50 (66%)
CpG 74-78
P = 3,2E-03
HR = 0,35
16/50 (32%)
34/50 (68%)
9/50 (18%)
41/50 (82%)
CpG 74-78
P = 5,7E-02
HR = 0,44
A
B
C
Fig. 3 Kaplan–Meier analysis of overall survival (OS) in the indepen-
dent validation cohort of 50 GBM patients. a A cut-off value of 9 % for
CpG 74–78 was used (optimal risk cut-off in the initial population of 89
GBM patients). Cut-off values of 10 (b) and 28 (c) for CpG 74–78 were
used (cut-offs obtained by a boostrap procedure based on 1,000
resamplings in the initial population of 89GBM patients). M patients
with a value above the calculated cut-off and therefore considered as
methylated, UM patients with a value below or equal to the calculated cut-
off and therefore considered as unmethylated. NR not reached
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outcome-based cut-off for each CpG, as carried out in a
previous study [10]. In this previous study using the
Qiagen PSQ test (CpGs 74–78), the optimized cut-offs
were very similar for OS (4, 11, 6, 6, 5 and 8) and PFS
(4,4,8,6,4 and 8) to the values obtained in the present
study for OS (8, 11, 5, 7, 4 and 9) and for PFS (8, 5, 8, 6,
4 and 7), concerning CpG 74, CpG 75, CpG 76, CpG 77,
CpG 78 and mean CpG 74–78, respectively. In the
present study we also validated the cut-off of 9 % (mean
values CpG 74–78) in an independent cohort of 50 GBM
patients. As frozen tumor tissue is not always available in
daily practice, for this cohort of patients, we worked with
FFPE samples. Recently, Reifenberger et al. [15] found a
good degree of concordance between PSQ and MS-PCR:
at a cut-off of 8 % (mean values CpG 74–78) 153/166
(92 %) of patients were identically classified. Further-
more, for patients treated with chemotherapy, PSQ and
MS-PCR looked similar to predict outcome in this series
of elderly patients ([70 years). In their study, Bady et al.
[22] used an external data-set of 50 GBM patients that
had been pyrosequenced by our group. Using an iterative
procedure based on segmented regression, these authors
estimated the cut-off at 7.28 % average methylation. This
shows that PSQ is a robust technique and several reports
are now available that agree on the best cut-off for the
most commonly used PSQ test (the mean of CpGs 74–78)
being around 9 %.
In conclusion, the methylation levels at several indi-
vidual CpGs sites or combinations of CpGs in the MGMT
CpG island determined by PSQ—some of which were
previously found to be correlated with MGMT expres-
sion—are highly significant predictive markers for GBM
patients treated with the current standard care treatment.
CpGs 84, 89 and mean CpGs 84–88 appear particularly
useful. The mean of CpGs 74–78 was also among the CpGs
or combinations of CpGs most strongly associated with the
outcome of patients. Because (1) a commercial kit is
available for determining the level of methylation of these
5 CpGs by PSQ, which makes it easy to standardize the test
(2) this kit is currently successfully used by different
groups (3) we can now be confident about the best cut-off
allowing stratification of patients into good and poor
responders to TMZ, we recommend to test CpGs 74–78 for
PSQ with the PyroMark CpG MGMT kit and use the mean
methylation of all 5 CpGs to determine the MGMT
methylation status.
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